Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.

Buckmelter AJ, Ren L, Laird ER, Rast B, Miknis G, Wenglowsky S, Schlachter S, Welch M, Tarlton E, Grina J, Lyssikatos J, Brandhuber BJ, Morales T, Randolph N, Vigers G, Martinson M, Callejo M.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1248-52. doi: 10.1016/j.bmcl.2010.12.039. Epub 2010 Dec 10.

PMID:
21211972
2.

Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.

Duffey MO, Adams R, Blackburn C, Chau RW, Chen S, Galvin KM, Garcia K, Gould AE, Greenspan PD, Harrison S, Huang SC, Kim MS, Kulkarni B, Langston S, Liu JX, Ma LT, Menon S, Nagayoshi M, Rowland RS, Vos TJ, Xu T, Yang JJ, Yu S, Zhang Q.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4800-4. doi: 10.1016/j.bmcl.2010.06.113. Epub 2010 Jun 25.

PMID:
20634068
3.

Non-oxime inhibitors of B-Raf(V600E) kinase.

Ren L, Wenglowsky S, Miknis G, Rast B, Buckmelter AJ, Ely RJ, Schlachter S, Laird ER, Randolph N, Callejo M, Martinson M, Galbraith S, Brandhuber BJ, Vigers G, Morales T, Voegtli WC, Lyssikatos J.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1243-7. doi: 10.1016/j.bmcl.2010.12.061. Epub 2010 Dec 19.

PMID:
21251822
4.

Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.

Blackburn C, Duffey MO, Gould AE, Kulkarni B, Liu JX, Menon S, Nagayoshi M, Vos TJ, Williams J.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4795-9. doi: 10.1016/j.bmcl.2010.06.110. Epub 2010 Jun 25.

PMID:
20630752
5.

The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.

Takle AK, Bamford MJ, Davies S, Davis RP, Dean DK, Gaiba A, Irving EA, King FD, Naylor A, Parr CA, Ray AM, Reith AD, Smith BB, Staton PC, Steadman JG, Stean TO, Wilson DM.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4373-6. doi: 10.1016/j.bmcl.2008.06.070. Epub 2008 Jun 24.

PMID:
18621524
6.

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.

Stellwagen JC, Adjabeng GM, Arnone MR, Dickerson SH, Han C, Hornberger KR, King AJ, Mook RA Jr, Petrov KG, Rheault TR, Rominger CM, Rossanese OW, Smitheman KN, Waterson AG, Uehling DE.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4436-40. doi: 10.1016/j.bmcl.2011.06.021. Epub 2011 Jun 16.

PMID:
21733693
7.

Discovery of highly potent and selective type I B-Raf kinase inhibitors.

Wang X, Berger DM, Salaski EJ, Torres N, Hu Y, Levin JI, Powell D, Wojciechowicz D, Collins K, Frommer E.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6571-4. doi: 10.1016/j.bmcl.2009.10.030. Epub 2009 Oct 13.

PMID:
19854649
8.

Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.

Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R.

Bioorg Med Chem Lett. 2009 May 15;19(10):2735-8. doi: 10.1016/j.bmcl.2009.03.129. Epub 2009 Mar 28.

PMID:
19362830
9.

Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.

Smith AL, DeMorin FF, Paras NA, Huang Q, Petkus JK, Doherty EM, Nixey T, Kim JL, Whittington DA, Epstein LF, Lee MR, Rose MJ, Babij C, Fernando M, Hess K, Le Q, Beltran P, Carnahan J.

J Med Chem. 2009 Oct 22;52(20):6189-92. doi: 10.1021/jm901081g.

PMID:
19764794
10.

Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.

Wenglowsky S, Moreno D, Laird ER, Gloor SL, Ren L, Risom T, Rudolph J, Sturgis HL, Voegtli WC.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6237-41. doi: 10.1016/j.bmcl.2012.08.007. Epub 2012 Aug 10.

PMID:
22954737
11.

3,5-Disubstituted-indole-7-carboxamides: the discovery of a novel series of potent, selective inhibitors of IKK-β.

Miller DD, Bamborough P, Christopher JA, Baldwin IR, Champigny AC, Cutler GJ, Kerns JK, Longstaff T, Mellor GW, Morey JV, Morse MA, Nie H, Rumsey WL, Taggart JJ.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2255-8. doi: 10.1016/j.bmcl.2011.02.107. Epub 2011 Mar 1.

PMID:
21429745
12.

Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.

Berger DM, Torres N, Dutia M, Powell D, Ciszewski G, Gopalsamy A, Levin JI, Kim KH, Xu W, Wilhelm J, Hu Y, Collins K, Feldberg L, Kim S, Frommer E, Wojciechowicz D, Mallon R.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6519-23. doi: 10.1016/j.bmcl.2009.10.049. Epub 2009 Oct 26.

PMID:
19864136
13.

The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.

Tang J, Lackey KE, Dickerson SH.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):66-70. doi: 10.1016/j.bmcl.2012.11.020. Epub 2012 Nov 16.

PMID:
23218715
14.

Recent advances in the research and development of B-Raf inhibitors.

Li HF, Chen Y, Rao SS, Chen XM, Liu HC, Qin JH, Tang WF, Yue-Wang, Zhou X, Lu T.

Curr Med Chem. 2010;17(16):1618-34. Review.

PMID:
20345352
15.

Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.

Shih KC, Lin CY, Zhou J, Chi HC, Chen TS, Wang CC, Tseng HW, Tang CY.

J Chem Inf Model. 2011 Feb 28;51(2):398-407. doi: 10.1021/ci100351s. Epub 2010 Dec 23.

PMID:
21182293
16.

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Wenglowsky S, Ahrendt KA, Buckmelter AJ, Feng B, Gloor SL, Gradl S, Grina J, Hansen JD, Laird ER, Lunghofer P, Mathieu S, Moreno D, Newhouse B, Ren L, Risom T, Rudolph J, Seo J, Sturgis HL, Voegtli WC, Wen Z.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5533-7. doi: 10.1016/j.bmcl.2011.06.097. Epub 2011 Jul 2.

PMID:
21802293
17.

Potent and selective pyrazole-based inhibitors of B-Raf kinase.

Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson M, Laird E, Brandhuber BJ, Vigers G, Morales T, Woessner R, Randolph N, Lyssikatos J, Olivero A.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4692-5. doi: 10.1016/j.bmcl.2008.07.002. Epub 2008 Jul 5.

PMID:
18676143
18.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Woods KW, Fischer JP, Claiborne A, Li T, Thomas SA, Zhu GD, Diebold RB, Liu X, Shi Y, Klinghofer V, Han EK, Guan R, Magnone SR, Johnson EF, Bouska JJ, Olson AM, de Jong R, Oltersdorf T, Luo Y, Rosenberg SH, Giranda VL, Li Q.

Bioorg Med Chem. 2006 Oct 15;14(20):6832-46. Epub 2006 Jul 14.

PMID:
16843670
19.

Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.

Selness SR, Devraj RV, Monahan JB, Boehm TL, Walker JK, Devadas B, Durley RC, Kurumbail R, Shieh H, Xing L, Hepperle M, Rucker PV, Jerome KD, Benson AG, Marrufo LD, Madsen HM, Hitchcock J, Owen TJ, Christie L, Promo MA, Hickory BS, Alvira E, Naing W, Blevis-Bal R.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5851-6. doi: 10.1016/j.bmcl.2009.08.082. Epub 2009 Aug 27.

PMID:
19751974
20.

Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.

Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y, Okada K, Inoue Y, Yamamoto Y, Nakagawa H, Yao S, Kawamoto T, Uchikawa O.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9. doi: 10.1016/j.bmcl.2012.10.084. Epub 2012 Oct 23.

PMID:
23147077

Supplemental Content

Support Center